Trojan, Lutz

[["dc.bibliographiccitation.firstpage","1706"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Cancer"],["dc.bibliographiccitation.lastpage","1712"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Zschäbitz, Stefanie"],["dc.contributor.author","Erlmeier, Franziska"],["dc.contributor.author","Stöhr, Christine"],["dc.contributor.author","Herrmann, Edwin"],["dc.contributor.author","Polifka, Iris"],["dc.contributor.author","Agaimy, Abbas"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Wülfing, Christian"],["dc.contributor.author","Steffens, Sandra"],["dc.date.accessioned","2022-05-02T08:09:39Z"],["dc.date.available","2022-05-02T08:09:39Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.7150/jca.63509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107432"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.issn","1837-9664"],["dc.title","Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Walleck, Eiko"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2018-11-07T09:28:04Z"],["dc.date.available","2018-11-07T09:28:04Z"],["dc.date.issued","2013"],["dc.identifier.isi","000333679600131"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30688"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Analysis of putative resistance mechanisms in recent treatments targeting the androgen receptor in castration-resistant prostate cancer (CRPC)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1293"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Radiology"],["dc.bibliographiccitation.lastpage","1307"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Rücker, Gerta"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2019-08-05T10:33:02Z"],["dc.date.available","2019-08-05T10:33:02Z"],["dc.date.issued","2018"],["dc.description.abstract","Purpose To compare partial nephrectomy (PN), radiofrequency ablation (RFA), cryoablation (CRA) and microwave ablation (MWA) regarding oncologic, perioperative and functional outcomes. Material and methods The MEDLINE, EMBASE and COCHRANE libraries were searched for studies comparing PN, RFA, CRA or MWA and reporting on any-cause or cancer-specific mortality, local recurrence, complications or renal function. Network meta-analyses were performed. Results Forty-seven studies with 24,077 patients were included. Patients receiving RFA, CRA or MWA were older and had more comorbidities compared with PN. All-cause mortality was higher for CRA and RFA compared with PN (incidence rate ratio IRR = 2.58, IRR = 2.58, p < 0.001, respectively). No significant differences in cancer-specific mortality were evident. Local recurrence was higher for CRA, RFA and MWA compared with PN (IRR = 4.13, IRR = 1.79, IRR = 2.52, p < 0.05 respectively). A decline in renal function was less pronounced after RFA versus PN, CRA and MWA (mean difference in GFR MD = 6.49; MD = 5.82; MD = 10.89, p < 0.05 respectively). Conclusion Higher overall survival and local control of PN compared with ablative therapies did not translate into significantly better cancer-specific mortality. Most studies carried a high risk of bias by selecting younger and healthier patients for PN, which may drive superior survival and local control. Physicians should be aware of the lack of high-quality evidence and the potential benefits of ablative techniques for certain patients, including a superior complication profile and renal function preservation. Key Points • Patients selected for ablation of small renal masses are older and have more comorbidities compared with those undergoing partial nephrectomy. • Partial nephrectomy yields lower all-cause mortality, which is probably biased by patient selection and does not translate into prolonged cancer-free survival. • The decline of renal function is smallest after radiofrequency ablation for small renal masses."],["dc.identifier.doi","10.1007/s00330-018-5660-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62282"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0938-7994"],["dc.relation.issn","1432-1084"],["dc.title","Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","372"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European Journal of Surgical Oncology (EJSO)"],["dc.bibliographiccitation.lastpage","379"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Buchner, A."],["dc.contributor.author","May, M."],["dc.contributor.author","Burger, M."],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Herrmann, E."],["dc.contributor.author","Fritsche, H.-M."],["dc.contributor.author","Ellinger, Joerg"],["dc.contributor.author","Hoefner, Thomas"],["dc.contributor.author","Nuhn, P."],["dc.contributor.author","Gratzke, C."],["dc.contributor.author","Brookman-May, Sabine"],["dc.contributor.author","Melchior, S."],["dc.contributor.author","Peter, J."],["dc.contributor.author","Moritz, R."],["dc.contributor.author","Tilki, Derya"],["dc.contributor.author","Gilfrich, Christian"],["dc.contributor.author","Roigas, Jan"],["dc.contributor.author","Zacharias, Mario"],["dc.contributor.author","Hohenfellner, Markus"],["dc.contributor.author","Haferkamp, Axel"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Wieland, Wolf F."],["dc.contributor.author","Mueller, S. C."],["dc.contributor.author","Stief, Christian G."],["dc.contributor.author","Bastian, Patrick J."],["dc.date.accessioned","2018-11-07T09:26:48Z"],["dc.date.available","2018-11-07T09:26:48Z"],["dc.date.issued","2013"],["dc.description.abstract","Aim: The outcome of patients with urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC) shows remarkable variability. We evaluated the ability of artificial neural networks (ANN) to perform risk stratification in UCB patients based on common parameters available at the time of RC. Methods: Data from 2111 UCB patients that underwent RC in eight centers were analysed; the median follow-up was 30 months (IQR: 12-60). Age, gender, tumour stage and grade (TURB/RC), carcinoma in situ (TURB/RC), lymph node status, and lymphovascular invasion were used as input data for the ANN. Endpoints were tumour recurrence, cancer-specific mortality (CSM) and all-cause death (ACD). Additionally, the predictive accuracies (PA) of the ANNs were compared with the PA of Cox proportional hazards regression models. Results: The recurrence-, CSM-, and ACD- rates after 5 years were 36%, 33%, and 46%, respectively. The best ANN had 74%, 76% and 69% accuracy for tumour recurrence, CSM and ACD, respectively. Lymph node status was one of the most important factors for the network's decision. The PA of the ANNs for recurrence, CSM and ACD were improved by 1.6% (p = 0.247), 4.7% (p < 0.001) and 3.5% (p = 0.007), respectively, in comparison to the Cox models. Conclusions: ANN predicted tumour recurrence, CSM, and ACD in UCB patients after RC with reasonable accuracy. In this study, ANN significantly outperformed the Cox models regarding prediction of CSM and ACD using the same patients and variables. ANNs are a promising approach for individual risk stratification and may optimize individual treatment planning. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ejso.2013.02.009"],["dc.identifier.isi","000316511800010"],["dc.identifier.pmid","23465180"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30384"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0748-7983"],["dc.title","Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3010"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Delonge, Laura M."],["dc.contributor.author","Haack, Anna-Maria"],["dc.contributor.author","Shuch, Brian"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2021-04-14T08:31:08Z"],["dc.date.available","2021-04-14T08:31:08Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12103010"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83497"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","574"],["dc.bibliographiccitation.journal","SpringerPlus"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:33:49Z"],["dc.date.available","2018-11-07T09:33:49Z"],["dc.date.issued","2014"],["dc.description.abstract","Recent breakthrough therapies targeting androgen receptor signalling in castration resistant prostate cancer (CRPC) involve multifunctional androgen receptor (AR) blockade and exhaustive androgen deprivation. Nevertheless, limitations to an enduring effectiveness of new drugs are anticipated in resistance mechanisms occurring under such treatments. In this study we used CRPC cell models VCaP and LNCaP as well as AR-negative PC-3- and non-neoplastic epithelial BPH-1-cells treated with 5, 10 or 25 mu mol/L abiraterone hydrolyzed from abiraterone acetate (AA). The origin of CYP17A1 up-regulation under AA treatment was investigated in CRPC cell models by qRT-PCR and western-blot procedures. AA treatments of AR positive CRPC cell models led to decreased expression of androgen regulated genes such as PSA. In these cells diminished expression of androgen regulated genes was accompanied by an up-regulation of CYP17A1 expression within short-term treatments. No such effects became evident in AR-negative PC-3 cells. AR directed siRNA (siAR) used in VCaP cells significantly reduced mRNA expression and AR protein abundance. Such interference with AR signalling in the absence of abiraterone acetate also caused a marked up-regulation of CYP17A1 expression. Down-regulation of androgen regulated genes occurs in spite of an elevated expression of CYP17A1, the very target enzyme for this drug. CYP17A1 up-regulation already takes place within such short treatments with AA and does not require adaptation events over several cell cycles. CYP17A1 is also up-regulated in the absence of AA when AR signalling is physically eliminated by siAR. These results reveal an immediate counter-regulation of CYP17A1 expression whenever AR-signalling is inhibited adequately but not a persisting adaptation yielding drug resistance."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft (DFG)"],["dc.identifier.doi","10.1186/2193-1801-3-574"],["dc.identifier.isi","000359105300002"],["dc.identifier.pmid","25332874"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11151"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32049"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","2193-1801"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Brookman-May, Sabine"],["dc.contributor.author","Bremmer, Felix"],["dc.date.accessioned","2018-11-07T09:43:56Z"],["dc.date.available","2018-11-07T09:43:56Z"],["dc.date.issued","2014"],["dc.identifier.isi","000335318100157"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34286"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Genitourinary Cancers Symposium"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","In vitro reproduction and explanation of an abiraterone acetate withdrawal phenomenon."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","564"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Vascular and Interventional Radiology"],["dc.bibliographiccitation.lastpage","571"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Kim, Hyun S."],["dc.date.accessioned","2020-12-10T15:20:09Z"],["dc.date.available","2020-12-10T15:20:09Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.jvir.2019.11.009"],["dc.identifier.issn","1051-0443"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72570"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Die Urologie"],["dc.contributor.author","Reichert, M."],["dc.contributor.author","Schüler, P."],["dc.contributor.author","Stepniewski, A."],["dc.contributor.author","Felmerer, G."],["dc.contributor.author","Trojan, L."],["dc.contributor.author","von Knobloch, H. C."],["dc.date.accessioned","2022-10-04T10:21:22Z"],["dc.date.available","2022-10-04T10:21:22Z"],["dc.date.issued","2022"],["dc.description.abstract","Zusammenfassung\n Unter Berücksichtigung einiger Grundprinzipien der Fistelchirurgie gibt es verschiedene Möglichkeiten der operativen Sanierung urethrorektaler Fisteln. Ein Standard, welche Operationsmethode unter welchen Umständen eingesetzt werden sollte, gibt es – auch aufgrund der Heterogenität dieser Erkrankung – nicht. Dieser Fall beschreibt die individuelle Adaptation einer Operationstechnik, welche zur Behandlung vesikovaginaler Fisteln eingesetzt wird, auf die Behandlung einer urethrorektalen Fistel eines Patienten nach bereits frustranem Versuch eines Fistelverschlusses, welche auf Basis einer etablierten Methode unter Verwendung eines Interponats zum Erfolg führte."],["dc.description.abstract","Abstract\n When taking into consideration the basic principles of fistula surgery, numerous options are available for the surgical repair of rectourethral fistulas. However, there is no standard regarding which surgical method should be used under which circumstances—due to the heterogeneity of this disease. This case report describes the individual adaptation of a surgical technique that is used for the treatment of vesicovaginal fistulas to treat a rectourethral fistula in a patient who had already undergone an unsuccessful fistula closure attempt. Successful closure of the fistula was achieved on the basis of an established method using tissue interposition."],["dc.identifier.doi","10.1007/s00120-022-01924-2"],["dc.identifier.pii","1924"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114393"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-600"],["dc.relation.eissn","2731-7072"],["dc.relation.issn","2731-7064"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Verschluss einer persistierenden urethrorektalen Fistel nach suprasymphysärer Adenomenukleation der Prostata durch kombiniertes Bressel-Naujox- mit einem Gracilisflapverfahren"],["dc.title.translated","Closure of persisting rectourethral fistula after suprasymphyseal adenoma enucleation of the prostate by combining the Bressel-Naujox and gracilis flap procedure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","ENDOCRINE CONNECTIONS"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Belharazem, Djeda"],["dc.contributor.author","Kirchner, Matthias"],["dc.contributor.author","Geissler, Franziska"],["dc.contributor.author","Bugert, Peter"],["dc.contributor.author","Spahn, Martin"],["dc.contributor.author","Kneitz, Burkhard"],["dc.contributor.author","Riedmiller, Hubertus"],["dc.contributor.author","Sauer, Christian"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Michel, Maurice Stephan"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Stroebel, Philipp"],["dc.date.accessioned","2018-11-07T09:04:21Z"],["dc.date.available","2018-11-07T09:04:21Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Insulin-like growth factor 2 (IGF2) is the predominant IGF in adults and regulates cell growth. In contrast to normal tissues, where IGF2 is imprinted and only expressed from the paternal allele, loss of imprinting (LOI) and biallelic IGF2 expression are observed in many cancers including prostate cancer (PCa). We here studied whether LOI of IGF2 in normal circulating peripheral blood lymphocytes can predict increased PCa risk. Samples and methods: We analyzed IGF2 protein levels, IGF2 820G/A genotype and imprinting status, as well as methylation status of the IGF2 imprinting control region (ICR) in 113 blood samples of patients with a history of radical prostatectomy (RPE) for PCa by ELISA, restriction-fragment length polymorphism, and bisulfite-DNA sequencing. Results were compared to 249 male blood donors with unknown prostate specific antigen (PSA) status. Results: The 820G/A genotype was enriched in the RPE group and was associated with younger age at cancer diagnosis. LOI in patients was only slightly more frequent than in controls, but IGF2 levels were significantly higher and uncoupled from the imprinting status. Analysis of the IGF2/H19 ICR revealed marked hypermethylation. Conclusions: The IGF 820G/A genotype is associated with PCa diagnosis at younger age. Increased IGF2 in patients with PCa appears to be the result of impaired imprinting in non-neoplastic cells rather than a paracrine tumor product. Uncoupling of IGF2 protein levels from imprinting status (not LOI alone) and hypermethylation of the ICR characterized PCa patients and could have the potential to indicate persons at risk in screening programs."],["dc.identifier.doi","10.1530/EC-12-0054"],["dc.identifier.isi","000209773300005"],["dc.identifier.pmid","23781309"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25099"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bioscientifica Ltd"],["dc.relation.issn","2049-3614"],["dc.title","Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]